npj Parkinson's Disease (Mar 2024)
Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
Abstract
No abstracts available.
npj Parkinson's Disease (Mar 2024)